13F Pro quality score
Rank #2,504 of 2,964
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Alzamend Neuro, Inc. (ALZN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALZN at 30.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,504 of 2,964 stocks — the bottom half of the AI-ranked universe. ALZN scores in the top quartile across institutional flow (99.5). Areas of concern include balance sheet strength (0.9) and earnings quality (26.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of ALZN by reported 13-F value include Kingsbury Capital Investment Advisors, KMT WEALTH MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. ALZN trades on the Nasdaq exchange and files with the SEC under CIK 1677077. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALZN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alzamend Neuro, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1677077 →